Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP3.0 + Bifidobacterium longum subsp. infantis
- Development stage
- Preclinical
- Lead developer
- South China University of Technology
- Modality
- Hydrogel Systems → Drug Delivery Systems, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
AP3.0 + Bifidobacterium longum subsp. infantis is an experimental oral microbial therapy consisting of the probiotic bacterium *Bifidobacterium longum subsp. infantis* (specifically strain GIM 1.207) encapsulated within an advanced enzyme-triggered, colon-targeted microcapsule (AP3.0). This delivery system is designed to protect the live biotherapeutic from the acidic environment of the stomach and bile salts in the small intestine, ensuring targeted release in the colon where microbial enzymes trigger the microcapsule's degradation. The formulation is primarily investigated for the treatment of ulcerative colitis, where it aims to restore gut microbiota balance, enhance the abundance of beneficial taxa such as *Bacteroidetes* and *Firmicutes*, and reduce intestinal inflammation by modulating pro-inflammatory cytokines. Preclinical studies suggest it may be more effective than standard anti-inflammatory treatments like mesalazine in regulating intestinal flora and alleviating colitis symptoms.
- Other names
- AP3.0 + Bifidobacterium longum subsp. infantis GIM 1.207AP3.0 encapsulated Bifidobacterium infantisAP-3.0 encapsulated Bifidobacterium infantisAP 3.0 encapsulated Bifidobacterium infantis
02
Targets
IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on AP3.0 + Bifidobacterium longum subsp. infantis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP3.0 + Bifidobacterium longum subsp. infantis.